20220426_CP_CONITEC_016_2022_Tec_acido
2022
20220426_CP_CONITEC_017_2022_Exp_Eltrombopague
20220426_CP_CONITEC_017_2022_Tec_Eltrombopague
20220426_CP_CONITEC_018_2022_Exp_Ruxolitinibe
20220426_CP_CONITEC_018_2022_Tec_Ruxolitinibe
20220426_CP_CONITEC_019_2022_Exp_Denosumabe
20220426_CP_CONITEC_019_2022_Tec_Denosumabe
20220427_CP_CONITEC_012_2022_Exp_Ofatumumabe
20220427_CP_CONITEC_012_2022_Tec_Ofatumumabe
20220427_CP_CONITEC_013_2022_Exp_Dapagliflozina
20220427_CP_CONITEC_013_2022_Tec_Dapagliflozina
20220428_CP_CONITEC_022_2022_Exp_Nirmatrelvir
20220428_CP_CONITEC_022_2022_Tec_Nirmatrelvir
20220504_CP_CONITEC_020_2022_PCDT_de_Puberdade
20220510_CP_CONITEC_021_2022_PCDT_da_Profilaxia
20220511_CP_CONITEC_023_2022_Exp_Cladribina
20220511_CP_CONITEC_023_2022_Tec_Cladribina
20220518_CP_CONITEC_024_2022_PCDT_da_Alergia
20220518_CP_CONITEC_025_2022_Exp_Anticorpos
Contribuições da Consulta Pública - Formulário Técnico - Anticorpos monoclonais quimioterapia no tratamento de primeira linha do câncer colorretal metastático -